A Real‐World Phase IV Superiority Trial and Cost‐Effectiveness Analysis of the Addition of Low‐Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients

Documents similaires

• Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
  par: Aarti Bhatia, et autres
  Publié: (2025)
• Impact of Extranodal Extension in Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Systematic Review and Meta‐Analysis
  par: Andrea Costantino, et autres
  Publié: (2025)
• Beyond Low‐Dose CT : Rethinking Lung Cancer Screening in Survivors of Head and Neck Cancer
  par: Gavin Wayne Stoel, et autres
  Publié: (2026)
• Treatment Effect Estimation With Potential Outcomes for a Single‐Arm Trial Compared With Historical Controls: A Case Study of Locally Recurrent Head and Neck Squamous Cell Carcinoma Patients Treated With Adjuvant Nivolumab
  par: Nusrat Harun, et autres
  Publié: (2025)
• Prognosis After Discontinued Treatment due to Immune‐Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
  par: Hiromasa Ishihara, et autres
  Publié: (2025)